Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nelson

Showing results (261-270 of 442) with videos related to

Pageof 45
Sort By:
British Journal of Pharmacology|January 26, 2019
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular riskKirk A Taylor, Erica Smyth, Francesca Rauzi, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
Cell Research|July 1, 2004
Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patientsJustin Stebbing, Steve Patterson, Simon Portsmouth, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patientsEugenia Vispo, Muge Cevik, Juergen K Rockstroh, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patientsJennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Blood|July 9, 2004
Protease inhibitors potentiate chemotherapy-induced neutropeniaMark Bower, Neil McCall-Peat, Natalie Ryan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
AIDS (London, England)|December 22, 2007
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infectionKaren Tashima, Schlomo Staszewski, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 12, 2010
Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence?Rachael Jones, David Brown, Mark Nelson, et al.
Pageof 45

Showing results (261-270 of 442) with videos related to

Sort By:
Pageof 45
British Journal of Pharmacology|January 26, 2019
Pharmacological impact of antiretroviral therapy on platelet function to investigate human immunodeficiency virus-associated cardiovascular riskKirk A Taylor, Erica Smyth, Francesca Rauzi, et al.
The Journal of Antimicrobial Chemotherapy|September 21, 2006
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patientsJennifer Ford, Marta Boffito, Desmond Maitland, et al.
Cell Research|July 1, 2004
Studies on the allostimulatory function of dendritic cells from HCV-HIV-1 co-infected patientsJustin Stebbing, Steve Patterson, Simon Portsmouth, et al.
The Journal of Antimicrobial Chemotherapy|February 22, 2005
Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice dailyMarta Boffito, Desmond Maitland, Laura Dickinson, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 15, 2013
Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patientsEugenia Vispo, Muge Cevik, Juergen K Rockstroh, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patientsJennifer Ford, Marta Boffito, Adrian Wildfire, et al.
Blood|July 9, 2004
Protease inhibitors potentiate chemotherapy-induced neutropeniaMark Bower, Neil McCall-Peat, Natalie Ryan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patientsMarta Boffito, Laura Dickinson, Andrew Hill, et al.
AIDS (London, England)|December 22, 2007
Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infectionKaren Tashima, Schlomo Staszewski, Mark Nelson, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 12, 2010
Re-emergent hepatitis C viremia after apparent clearance in HIV-positive men who have sex with men: reinfection or late recurrence?Rachael Jones, David Brown, Mark Nelson, et al.
Pageof 45